EMODIN EFFICACY ON THE AKT, MAPK, ERK AND DNMT EXPRESSION PATTERN DURING DMBA-INDUCED ORAL CARCINOMA IN GOLDEN SYRIAN HAMSTERS by Manimaran, Asokan et al.
Manimaran et al., Afr J Tradit Complement Altern Med. (2016) 13(6):186-193 
10.21010/ajtcam. v13i6.27 
186 
 
EMODIN EFFICACY ON THE AKT, MAPK, ERK AND DNMT EXPRESSION PATTERN DURING 
DMBA-INDUCED ORAL CARCINOMA IN GOLDEN SYRIAN HAMSTERS 
 
Asokan Manimaran, Shanmugam Manoharan* and Mani Neelakandan 
 
Department of Biochemistry and Biotechnology, Faculty of Science, Annamalai University, 
Annamalainagar - 608002, Tamilnadu, India. 
 
* Corresponding author E-mail: sakshiman@rediffmail.com    
 
Abstract 
 
Background: The present study has evaluated the Emodin efficacy on the Akt, MAPK, ERK and DNMT expression pattern during 
7,12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinoma in golden Syrian hamsters, in order to explore its antitumor 
potential.  
Materials and methods: Oral tumors were developed in the buccal pouches of golden Syrian hamsters using the carcinogen, 
DMBA.  
Results: While the incidence of tumor formation was 100% in hamsters treated with DMBA alone, the tumor formation was not 
noticed in DMBA+ Emodin treated hamsters. Also, Emodin reduced the severity of precancerous pathological lesions such as 
dysplasia, in the hamsters treated with DMBA. Emodin administration corrected the abnormalities in the expression pattern of Akt, 
MAPK, ERK and DNMT in the buccal mucosa of hamsters treated with DMBA.  
Conclusions: The present study thus suggests that the tumor preventive potential of Emodin is partly related to its modulating effect 
on the Akt, MAPK, ERK and DNMT expression pattern, as these molecular markers have a pivotal role in the process of cell 
proliferation, inflammation, invasion, and apoptosis. 
Keywords: Oral carcinoma, Akt, MAPK, DNMT. 
 
 
Introduction 
 
Oral squamous cell carcinoma, a cancer of the oral cavity, is one of the ten most common malignant neoplasms and is the 
5th most frequent cancer worldwide (Markopoulos, 2012). The development of oral cancer is usually preceded by distinct 
precancerous lesions such as leukoplakia, erythroplakia and oral submucous fibrosis. However, the potential or degree of malignant 
transformation varies from one another (Carnelio et al., 2011). Oral carcinoma has a spectrum of risk factors, which include tobacco, 
alcohol, diet and nutrition, betel quid, viruses, immune deficiency and poor oral hygiene (Khyani et al., 2015). Tobacco chewing 
together with tobacco smoking, betel quid chewing and alcohol abuse is recognized as the strongest risk factor of oral cancer 
(Sridharan, 2014). Several epidemiological and aetiological studies pointed out the synergistic efficacy of tobacco and alcohol in the 
development of oral carcinoma (Patil et al., 2013). Although oral cancer is common in several countries, the highest incidence is 
reported every year from India, Pakistan, Sri Lanka, France and Hungary (Vigneswaran and Williams, 2014). The behavioral risk 
factors, tobacco and alcohol, accounts for 75-95% of all oral cancers in India (Gupta et al., 2013). Creating awareness on the risk 
factors of oral cancer to the public could help to reduce the annual incidence, since the risk factors are avoidable one (El Rhazi et al., 
2014). It has also been pointed out that early diagnosis will improve the survival outcome of the patients (80%) and quality of life 
than diagnosis at late stage [30%] (Baykul et al., 2010).  
Golden Syrian hamsters serve as an ideal model to study the tumor inhibitory potential of natural products, especially in 
oral carcinoma (Steele and Lubet, 2010). Hamsters possess buccal pouches (a pocket like anatomy) on their oral cavity, which can 
retain the carcinogen for the longest time when applied topically and thus tumors develop within a shorter duration (Chen et al., 
2012). DMBA induces buccal pouch carcinogenesis in the hamsters through inducing chronic inflammation, causing extensive 
oxidative DNA damage and by inducing DNA mutations (Ismail et al., 2016). Oral cancer chemoprevention researchers prefer 
DMBA induced hamster buccal pouch carcinogenesis model, as this model exhibits close resemblance and similarities with human 
oral tumor in many aspects, including at histopathological and molecular levels (Manoharan et al., 2016; Casto et al., 2013). 
 P13K/Akt and ERK/MAPK pathways perform a pivotal role in the regulation of tumor growth, progression, invasion and 
metastasis (Gan et al., 2010). As P13K/Akt pathways play crucial and critical role in both cell survival and apoptotic pathway, their 
abnormal regulation or expression could mediate the neoplastic transformation in various cancers including oral carcinoma (Chang 
et al., 2013). The status of p-Akt has been focused as an independent prognostic marker in various cancers. Inhibition of P13K/Akt 
pathway was resulted in the induction of apoptotic cascade in various cancers (Matsuoka and Yashiro, 2014). P13K/Akt pathway 
was significantly activated during oral carcinogenesis. Tumor growth inhibition could thus be achieved by blocking the activation of 
Akt or ERK signaling pathways (Chappell et al., 2011).  
 MAPK family plays an important role in cell differentiation, proliferation, inflammation and apoptosis. This family also 
consists of ERK and P38. Profound studies pointed out that P38 MAPK are activated by a bundle of stimuli such as growth factors, 
cytokines and chemical stresses, resulting in cell proliferation, migration and apoptosis (Gerthoffer et al., 2012). MAPK has also a 
pivotal role in the regulation of angiogenesis. ERK, a subfamily of the MAPK family, plays an important role in the regulation of 
cell differentiation and proliferation (Munshi and Ramesh, 2013). ERK has been identified as a positive regulator of cell cycle and it 
stimulates cyclic dependent kinases - cyclin D complex, which is essential for the progression of the cell cycle (Villanueva et al., 
2007). Several studies have pointed out that the accumulation of activated ERK (pERK) in the nucleus could result in genomic 
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instability as well as promotes tumorigenesis. ERK also has a role in the stimulation of tumor suppressor pathways (Bobrovnikova et 
al., 2010). DNA methylation, a major factor in epigenetic phenomenon, plays prominent role in the process of carcinogenesis. The 
enzyme DNA methyl transferease (DNMT) regulates the process of DNA methylation (Jin et al., 2011). Profound studies on various 
cancers documented the over expression of DNMT (Estève et al., 2016). Thus, DNMT has been utilised as a major target for cancer 
treatment. 
Emodin, an anthraquinone derivative, is present in the root and rhizome of several Chinese medicinal plants and used in 
traditional Chinese medicine to treat numerous illnesses (Yang et al., 2014). Profound studies documented the pharmacological, 
biochemical and therapeutic effects of Emodin using experimental animal models or via in vitro approach.  Emodin explored its 
cytotoxic  potential against various tumor cell lines including  human lung squamous carcinoma cells, human cervical cancer cells, 
human hepatoma cells, human breast cancer cells and human cervix epithelioid carcinoma cells (Zu et al., 2015; Yaoxian et al., 
2013;  Huang et al., 2013; Huang et al., 2013).  Emodin exerted apoptotic potential in various cancer cell lines. In vivo studies 
demonstrated its antidiabetic, hepatoprotective and anticancer properties (Zhao et al., 2009; Lin et al., 2012). The present study 
explores the Emodin efficacy on the Akt, MAPK, ERK and DNMT expression pattern during 7,12-dimethylbenz[a]anthracene 
(DMBA)-induced oral carcinoma. 
 
 
Materials and methods 
Animals 
 
 We procured forty golden Syrian hamsters, (male; 80-120g) from National Institute of Nutrition, Hyderabad, India and 
were maintained according to the Institutional ethical committee guidelines in the Central Animal House, Annamalai University 
(Registration Number 160/1999/ CPCSEA).  
 
Tumor induction 
  
The present study utilized DMBA, the site specific and organ specific carcinogen to produce tumors in the buccal pouches 
of golden Syrian hamsters. Topical application of this carcinogen (0.5% in liquid paraffin) three times a week for 14 weeks 
developed well differentiated squamous cell carcinoma (confirmed by oral pathologist, Annamalai University) 
 
Experimental design 
  
The experimental hamsters were divided into four groups of ten in each and housed in the polypropylene animal cages (5 
animals/cage). The experimental hamsters were provided with pellet diet and water ad libitum. The experimental protocol followed 
in the present study is given in the figure 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Experimental protocol 
 
Group I hamsters received liquid paraffin alone on their buccal pouches (topical application, three times a week for 14 
weeks) and served as a vehicle treated control. The buccal pouches of group II hamsters were exposed to 0.5% DMBA in liquid 
paraffin alone (Topical application; three times a week for 14 weeks) and served as carcinogen treated control. Group III hamsters 
were exposed to DMBA, as in group II, and were orally administered with Emodin (50mg/kg b.w), three times a week for 14 weeks; 
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on alternate days of DMBA painting. Group IV hamsters received Emodin alone orally (three times a week for 14 weeks). After the 
experimental period, the buccal mucosa was excised from all the experimental hamsters and subjected to Western blotting to assess 
the expression pattern of p-Akt, p-ERK, p-P38 MAPK, DNMT1, DNMT3a and DNMT3b 
 
 
 
Western blotting 
 
 The proteins were extracted from the buccal mucosa tissues and quantified (Bradford, 1976). The tissue extract was then 
subjected to polyacrylamide gel electrophoresis (PAGE) to separate the various proteins. Electroblotting was employed to transfer 
the separated protein bands onto PVDF membrane. The membrane containing protein blots were then incubated with the 
corresponding primary antibodies (p-Akt, p-ERK, p-P38 MAPK, DNMT1, DNMT3a and DNMT3b, Cell Signaling Technology, 
Danvers, MA, USA). After the incubation period the blot was treated with the secondary antibodies labelled with horseradish 
peroxidase (Santa Cruz Biotechnology, USA). The immune complex formed was then treated with  diaminobenzidine, and the bands 
were  scanned and analysed densitometrically (Bio-Rad Image Lab™ software version 4.1 software). 
 
Statistical analysis 
  
The statistical significance between the groups was assessed using One way analysis of variance (ANOVA) followed by 
Duncan's Multiple Range Test (DMRT). The results obtained were considered statistically significant if the p value was less than 
0.05 between the two groups. 
 
 
Results 
  
 Buccal mucosa p-Akt, p-ERK, p-P38 MAPK, DNMT1, DNMT3a and DNMT3b expression pattern obtained using 
Western blotting and their densitometry analysis in the control and experimental hamsters are given in the figures 2-5. Western blot 
analysis revealed over-expression of the above said molecular markers in the hamsters treated with DMBA alone when compared to 
control hamsters. Emodin administration orally at the dose of 50mg/kg b.w to the hamsters treated with DMBA brought back the 
expression pattern of all the markers to near normal range. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Expression pattern of p-Akt, p-P38 MAPK and p-ERK in the buccal pouch tissues of control and experimental animals    in 
each group. Lane 1: Control, Lane 2: DMBA alone, Lane 3: DMBA + Emodin, Lane 4: Emodin alone. 
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Figure 3: Densitometric analysis for p-Akt, p-P38 MAPK and p-ERK expression pattern in control and experimental animals in each 
group.Data presented are the mean ± SD (n=10).  Common superscripts between two groups - not significant. Different superscripts 
between two groups - significant p<0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Expression pattern of DNMT1, DNMT3a and DNMT3b in the buccal pouch tissues of control and experimental animals. 
Lane 1: Control, Lane 2: DMBA alone, Lane 3: DMBA + Emodin, Lane 4: Emodin alone.  
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Figure 5: Densitometric analysis for DNMT1, DNMT3a and DNMT3b expression pattern in control and experimental animals in 
each group. Data presented are the mean ± SD (n=10).  Common superscripts between two groups - not significant. Different 
superscripts between two groups - significant p<0.05. 
 
 
Discussion 
 
Oral cancer arises due to the abnormalities in multiple molecular pathways, which include pathways of cell proliferation, 
apoptosis, inflammation and angiogenesis (Manoharan et al., 2015). Extensive studies utilized these molecular pathways to evaluate 
the antitumor potential of the medicinal plants, their active constituents and synthetic agents (Schetter et al., 2010). The present 
study has utilized the Akt, MAPK, ERK and DNMT pathways to explore the Emodin efficacy in the inhibition of tumor formation 
during 7,12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinoma. 
 Akt and MAPK pathways are involved in the regulation of genes that play pivotal role in cell proliferation, inflammation, 
invasion, autophagy and apoptosis. Apoptosis and arrest of cell growth can be achieved by blocking Akt activation in tumor cells 
(Jiang and Liu, 2009). The Akt pathway plays an important role in the regulation of cell-cycle progression and tumor cell growth 
(Antico Arciuch et al., 2012). A large number of studies showed increased activity of Akt, a well known serine/ threonine kinase, in 
various types of malignancies including oral cancer (Lee, 2014). Upregulation of Akt/P38 MAPK signaling pathway has been 
reported in oral carcinoma HSC-3 cells. Akt mediates its self proliferative role via inhibiting pro-apoptotic proteins or promoting 
anti-apoptotic genes (Kalimuthu and Se-Kwon, 2013). Akt pathway was up-regulated in 30 to 60% of prostate carcinogenesis 
(Shtivelman et al., 2014).  
 A pro-apoptotic as well as anti-apoptotic role for P38 MAPK has been reported in tumor cells. Multiple evidences explored 
deregulation in P38MAPK signaling pathway, which has been associated with malignant transformation (Wagner and Nebreda, 
2009). Deregulation of MAPK pathway has been reported in several cancers, particularly in more than 50% of hepatocellular 
carcinomas. It has been reported that the mammary cancer metastasis can be inhibited by inhibiting P38 expression (Dhillon et al., 
2007). 
ERKs occupy the central position of diverse cellular signaling pathways that are involved in cell growth, proliferation and 
survival (Hong et al., 2015). Deregulation in the ERK / MAPK pathway is associated with the poor prognosis of oral cancer. 
ERK1/2 and P38, the subfamilies of MAPK, were deregulated in various carcinogenesis (Mebratu and Tesfaigzi, 2009). Aberrant 
ERK signaling could therefore lead to malignant transformation. ERK activation resulted in the activation of the spectrum of genes 
including PCNA, which in turn favors malignant transformation (Jin and Robertson, 2013). 
 There are three classes of DNMTs in the mammalian cells, DNMT1, DNMT3a and DNMT3b. DNMT1 is a maintenance 
methyltransferase and DNMT3a and DNMT3b are denovo methyltransferases (Liang et al., 2002). All three types of DNMT were 
abnormally expressed in cancerous conditions (Skowronski et al., 2010). DNMT1 plays prominent and pertinent role for DNA 
methylation during DNA replication. DNMT1 over expression was reported in lung, colorectal, prostate, breast, gastric and oral 
cavity cancers (Delpu et al., 2013). It has been pointed out that DNMT inhibition might lead to reactivation of the silenced genes. 
Down-regulation of p53 has been associated with up-regulation of DNMT1 (Au Yeung et al., 2010).  
Extensive studies reported the effect of Emodin on the Akt, MAPK, ERK and DNMT expression pattern in various cancer 
cell lines. Lin et al., (2016) pointed out that Emodin induced apoptotic process in the hepatic cancer cell lines via P13K/Akt and 
MAPK signaling pathways. Liu et al., (2015) explored the inhibitory effect of Emodin on the expression of P13K/Akt in the 
mechanical stress induced hypertrophic scarring. Emodin prevented the mammary cancer cell proliferation via down-regulating 
P13K/Akt protein expression (Sui et al., 2014). It has been reported that Akt down-regulation by Emodin is due to the inhibition of 
the components of the P13K pathway (Olsen et al., 2007). Zheng et al., (2015) observed that Emodin downregulated Akt expression 
in K562/Adr cells. Way et al., (2014) demonstrated that Emodin effectively inhibited the epithelial-mesenchymal transition in head 
and neck cancer cells via inhibiting Akt pathways.Inhibition of Akt activation has been suggested as a major mechanism of 
antitumor effect of Emodin against pancreatic cancer in mice (Wei et al., 2011). It has been pointed out that Emodin attenuated the 
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phosphorylation of P13K/Akt and ERK in HPG2 cells (Cui et al., 2016). Emodin exerted its antiinvasive property via down-
regulating ERK1/2 and Akt/PKB activation in glioma cells (Kim et al., 2005). Inactivation of ERK and Akt has been demonstrated 
in human lung adenocarcinoma cells (Su et al., 2005). Emodin downregulated the expression of DNMT1 and DNMT3 in pancreatic 
cancer cells. (Pan et al., 2016; Zhang et al., 2015). We, for the first time, demonstrated the modulating effect of emodin on the Akt, 
MAPK, ERK and DNMT expression pattern in experimental oral carcinogenesis. 
In the present study, we have explored the activation of Akt, ERK, P38 MAPK and DNMT, which have a crucial role in the 
process of cell proliferation, apoptosis and cell differentiation in the tumor bearing hamsters (DMBA alone treated hamsters). 
Emodin administration at a dose of 50mg/kg b.w to hamsters treated with DMBA inhibited the activation of all these molecular 
markers, as evidenced by the down regulation of these markers (Western blotting). The present study thus suggests that Emodin 
might have modulated the Akt, ERK, P38 MAPK and DNMT pathways towards suppression of tumor formation during DMBA 
induced oral carcinogenesis. 
 
Conclusion 
 
The present study concludes that the antitumor potential of Emodin might have partly attributed to its inhibitory effect on 
the activation of Akt, ERK, P38 MAPK and DNMT pathways during DMBA induced hamster buccal pouch carcinogenesis. 
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